Homology medicines, inc. (FIXX)
CashFlow / Yearly
Dec'19Dec'18Dec'17
Cash flows from operating activities:
Net loss

-103,916

-55,577

-29,991

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

6,318

1,289

684

Stock-based compensation expense

7,635

2,623

277

Amortization of premium on short-term investments

1,871

1,589

85

Loss on disposal of property and equipment

-13

-127

-

Change in fair value associated with convertible preferred stock tranche liability

-

-

876

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-2,759

5,003

1,463

Accounts payable

-4,452

4,383

1,720

Accrued expenses and other liabilities

2,315

3,042

864

Deferred revenue

-569

-1,890

33,411

Deferred rent

-410

-10,033

-186

Net cash used in operating activities

-91,358

-42,562

6,479

Purchases of short-term investments

286,391

245,328

78,071

Maturities of short-term investments

256,425

148,480

-

Purchases of property and equipment

21,833

24,939

1,958

Changes in restricted cash

-

-

1,497

Net cash provided by investing activities

-51,799

-121,787

-81,526

Cash flows from financing activities:
Proceeds from issuance of common stock pursuant to employee stock purchase plan

829

-

-

Proceeds from issuance of common stock in initial public offering, net of discounts and issuance costs

134,524

150,843

-

Repurchase of unvested common stock

-

-

17

Proceeds from issuance of common stock from option exercises

351

87

-

Proceeds from issuance of restricted common stock

-

64

-

Net cash provided by financing activities

158,213

150,994

115,230

Net change in cash, cash equivalents and restricted cash

15,056

-13,355

40,183

Reclassification of liability for common stock vested

60

75

225

Property and equipment additions included in accounts payable

455

9,127

167

Property and equipment additions included in accrued expenses and other liabilities

249

-

-

Unrealized gain on available for sale securities, net

260

-4

-

Offering costs included in accrued expenses and other liabilities

100

-

-

Deferred offering costs included in accrued expenses

-

-

1,000

Reclassification of tranche liability upon issuance of convertible preferred stock

-

-

5,123

ATM
Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs

22,509

-

-

Series A Convertible Preferred Stock
Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

20,479

Series B Convertible Preferred Stock
Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

94,768